CN102633796B - 一种苦参酸类衍生物的制备方法 - Google Patents
一种苦参酸类衍生物的制备方法 Download PDFInfo
- Publication number
- CN102633796B CN102633796B CN201210106833.7A CN201210106833A CN102633796B CN 102633796 B CN102633796 B CN 102633796B CN 201210106833 A CN201210106833 A CN 201210106833A CN 102633796 B CN102633796 B CN 102633796B
- Authority
- CN
- China
- Prior art keywords
- preparation
- formula
- methyl alcohol
- reaction
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 54
- 239000002253 acid Substances 0.000 title abstract description 44
- 241000246044 Sophora flavescens Species 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 51
- 238000006243 chemical reaction Methods 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 23
- 230000035484 reaction time Effects 0.000 claims abstract description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 87
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 54
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 27
- 238000003756 stirring Methods 0.000 claims description 26
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 22
- 239000007864 aqueous solution Substances 0.000 claims description 22
- -1 methoxy-benzyl Chemical group 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 17
- 239000011259 mixed solution Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 11
- 235000011152 sodium sulphate Nutrition 0.000 claims description 11
- 239000012043 crude product Substances 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 8
- 238000004440 column chromatography Methods 0.000 claims description 7
- 238000010511 deprotection reaction Methods 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- 239000007795 chemical reaction product Substances 0.000 claims description 4
- 238000005352 clarification Methods 0.000 claims description 4
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000007142 ring opening reaction Methods 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 6
- 208000002672 hepatitis B Diseases 0.000 abstract description 5
- 208000005176 Hepatitis C Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000009385 viral infection Effects 0.000 abstract description 3
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 abstract 2
- 229940101209 mercuric oxide Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 48
- 102000012215 HSC70 Heat-Shock Proteins Human genes 0.000 description 22
- 108010036652 HSC70 Heat-Shock Proteins Proteins 0.000 description 22
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 238000004113 cell culture Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000000452 restraining effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 11
- 229930014456 matrine Natural products 0.000 description 11
- 238000011084 recovery Methods 0.000 description 11
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 235000010290 biphenyl Nutrition 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 150000004702 methyl esters Chemical class 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 5
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 4
- 229940100630 metacresol Drugs 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 241000272525 Anas platyrhynchos Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 2
- JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 2
- UZGLOGCJCWBBIV-UHFFFAOYSA-N 3-(chloromethyl)pyridin-1-ium;chloride Chemical compound Cl.ClCC1=CC=CN=C1 UZGLOGCJCWBBIV-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000725618 Duck hepatitis B virus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- ITLHXEGAYQFOHJ-UHFFFAOYSA-N [diazo(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(=[N+]=[N-])C1=CC=CC=C1 ITLHXEGAYQFOHJ-UHFFFAOYSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- QYCSNMDOZNUZIT-UHFFFAOYSA-N benzhydrylidenehydrazine Chemical class C=1C=CC=CC=1C(=NN)C1=CC=CC=C1 QYCSNMDOZNUZIT-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000002508 compound effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- XMUPAAIHKAIUSU-QRQCRPRQSA-N kurarinol Chemical compound C1([C@H]2OC=3C(C[C@@H](CCC(C)(C)O)C(C)=C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1O XMUPAAIHKAIUSU-QRQCRPRQSA-N 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- LTTQKYMNTNISSZ-MWTRTKDXSA-N (2S)-(-)-kurarinone Chemical compound C1([C@H]2OC=3C(C[C@@H](CC=C(C)C)C(C)=C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1O LTTQKYMNTNISSZ-MWTRTKDXSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OTEKOJQFKOIXMU-UHFFFAOYSA-N 1,4-bis(trichloromethyl)benzene Chemical compound ClC(Cl)(Cl)C1=CC=C(C(Cl)(Cl)Cl)C=C1 OTEKOJQFKOIXMU-UHFFFAOYSA-N 0.000 description 1
- WZIYCIBURCPKAR-UHFFFAOYSA-N 4-(chloromethyl)pyridine Chemical compound ClCC1=CC=NC=C1 WZIYCIBURCPKAR-UHFFFAOYSA-N 0.000 description 1
- ZDHKVKPZQKYREU-UHFFFAOYSA-N 4-(chloromethyl)pyridine;hydron;chloride Chemical compound Cl.ClCC1=CC=NC=C1 ZDHKVKPZQKYREU-UHFFFAOYSA-N 0.000 description 1
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- YVBSAPDHRXHFHV-UHFFFAOYSA-N [chloro(methoxy)methyl]benzene Chemical compound COC(Cl)C1=CC=CC=C1 YVBSAPDHRXHFHV-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- XQVFLLMCNGKXSM-UHFFFAOYSA-N kurarinone Natural products COc1cc(O)c(C(CC=C(C)C)C(=C)C)c2OC(CC(=O)c12)c3ccc(O)cc3O XQVFLLMCNGKXSM-UHFFFAOYSA-N 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- KDADHLPROOOPIC-UHFFFAOYSA-N neokurarinol Natural products COc1cc(O)ccc1C1CC(=O)c2c(OC)cc(O)c(CC(CCC(C)(C)O)C(C)=C)c2O1 KDADHLPROOOPIC-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229930015582 oxymatrine Natural products 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (35)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210106833.7A CN102633796B (zh) | 2012-04-12 | 2012-04-12 | 一种苦参酸类衍生物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210106833.7A CN102633796B (zh) | 2012-04-12 | 2012-04-12 | 一种苦参酸类衍生物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102633796A CN102633796A (zh) | 2012-08-15 |
CN102633796B true CN102633796B (zh) | 2015-04-22 |
Family
ID=46618389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210106833.7A Expired - Fee Related CN102633796B (zh) | 2012-04-12 | 2012-04-12 | 一种苦参酸类衍生物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102633796B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104250247B (zh) * | 2013-06-28 | 2016-10-12 | 中国医学科学院医药生物技术研究所 | 新型槐定碱类衍生物槐定酸、槐定醇、槐定酯、槐定醚及其制备方法和用途 |
CN106279167B (zh) * | 2015-06-02 | 2018-11-13 | 中国医学科学院医药生物技术研究所 | 苦参碱类化合物衍生物及其制备方法和用途 |
CN117486882B (zh) * | 2023-11-08 | 2024-06-11 | 吉林农业大学 | 苦参碱类生物碱衍生物及其在制备多靶点多器官组织细胞损伤抑制剂中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102234279A (zh) * | 2010-04-30 | 2011-11-09 | 中国医学科学院医药生物技术研究所 | 苦参酸衍生物及其制备方法和用途 |
-
2012
- 2012-04-12 CN CN201210106833.7A patent/CN102633796B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102234279A (zh) * | 2010-04-30 | 2011-11-09 | 中国医学科学院医药生物技术研究所 | 苦参酸衍生物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN102633796A (zh) | 2012-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100534992C (zh) | 水飞蓟宾酯类衍生物及其制备方法和制备药物的用途 | |
CN103601683B (zh) | 苯并杂环类化合物及其制备方法和用途 | |
CN100596299C (zh) | 一类脱氢水飞蓟宾双酯类衍生物及其制备方法和用途 | |
CN104817574B (zh) | 喜树碱衍生物及其抗肿瘤应用 | |
CN110291065A (zh) | 一种新的异二氢吲哚衍生物、其药物组合物及应用 | |
CN101247807A (zh) | 噻唑化合物及使用方法 | |
CN101121698B (zh) | 二芳基嘧啶类衍生物及其制备方法和用途 | |
CN103275051B (zh) | 一种7,3’,4’-三羟基黄酮衍生物及其在制备治疗肝癌药物中的应用 | |
CN102633796B (zh) | 一种苦参酸类衍生物的制备方法 | |
CN106632383A (zh) | 莪术醇衍生物及其制备方法和在抗肿瘤药物中的应用 | |
CN107216352A (zh) | 线粒体靶向二氢吡啶衍生物及制备方法及应用 | |
CN103059030A (zh) | 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用 | |
CN108947949B (zh) | 抗焦虑氘代化合物及其医药用途 | |
CN105153190B (zh) | 含联芳基酰胺结构的杂环并嘧啶类化合物及其制备方法和应用 | |
CN101575327B (zh) | 一种抗疟活性异香豆素化合物及其组合物、制备方法和用途 | |
CN106892920A (zh) | 苦豆碱衍生物、其制备方法及用途 | |
CN103908447B (zh) | 苦参提取物和降苦参酮在抗ev71病毒感染中的应用 | |
CN108129366A (zh) | 抗病毒化合物、制备方法及其用途 | |
CN108451943B (zh) | 对环芳烷-氨基酸衍生物在制备病毒抑制剂方面的用途 | |
CN106928063A (zh) | 巨大戟二萜醇类化合物及其在抗hiv潜伏治疗上的应用 | |
CN105949214B (zh) | 去甲斑蝥素单酸钠盐衍生物及其抗肿瘤应用 | |
CN113087709A (zh) | 吡咯并嘧啶类衍生物及其制备方法和应用 | |
CN104744451A (zh) | 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途 | |
CN103044326A (zh) | 5-溴氧化异阿朴啡及其合成方法和应用 | |
WO2012075908A1 (zh) | 一类喹唑啉类化合物在制备抗黄病毒科病毒的药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ZHONGQI PHARM TECH (SHIJIAZHUANG) CO., LTD., SHIYA Free format text: FORMER OWNER: BIOMEDICAL TECHNOLOGY INST., CHINESE ACADEMY OF MEDICAL SCIENCES Effective date: 20130425 Owner name: BIOMEDICAL TECHNOLOGY INST., CHINESE ACADEMY OF ME Effective date: 20130425 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100050 DONGCHENG, BEIJING TO: 050035 SHIJIAZHUANG, HEBEI PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130425 Address after: 050035 the Yellow River Road, Hebei, Shijiazhuang, No. 226 Applicant after: Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. of CSPC Group Applicant after: Biomedical Technology Inst., Chinese Academy of Medical Sciences Address before: 100050 Beijing Tiantan, Dongcheng District, West Lane, No. 1 Applicant before: Biomedical Technology Inst., Chinese Academy of Medical Sciences |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150422 Termination date: 20210412 |